{"id":797565,"date":"2025-01-02T16:10:14","date_gmt":"2025-01-02T21:10:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/"},"modified":"2025-01-02T16:10:14","modified_gmt":"2025-01-02T21:10:14","slug":"terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/","title":{"rendered":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)"},"content":{"rendered":"
\n

FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the \u201cInducement Plan\u201d). The equity award was approved by the Compensation Committee of the Company\u2019s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee\u2019s acceptance of employment with Terns.<\/p>\n

The Company granted options to purchase 9,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $5.54, which was the closing price of Terns\u2019 common stock on December 31, 2024, which was the last trading day prior to the date of grant. The options vest over four years, subject to the employee\u2019s continued service through the applicable vesting dates.<\/p>\n

\n About Terns Pharmaceuticals<\/strong>\n <\/p>\n

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns\u2019 pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-\u03b2 agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com<\/a>.<\/p>\n

\n Contacts for Terns<\/strong>\n <\/p>\n

\n Investors<\/strong>
\n
Justin Ng
investors@ternspharma.com<\/a><\/p>\n

\n Media<\/strong>
\n
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the \u201cInducement Plan\u201d). The equity award was approved by the Compensation Committee of the Company\u2019s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee\u2019s acceptance of employment with Terns. The Company granted options to purchase 9,000 shares of Terns common stock … <\/p>\n

Continue reading “Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-797565","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the \u201cInducement Plan\u201d). The equity award was approved by the Compensation Committee of the Company\u2019s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee\u2019s acceptance of employment with Terns. The Company granted options to purchase 9,000 shares of Terns common stock … Continue reading "Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-02T21:10:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)\",\"datePublished\":\"2025-01-02T21:10:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"wordCount\":275,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/\",\"name\":\"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=\",\"datePublished\":\"2025-01-02T21:10:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/","og_locale":"en_US","og_type":"article","og_title":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","og_description":"FOSTER CITY, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (\u201cTerns\u201d or the \u201cCompany\u201d) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of January 1, 2025 an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended (the \u201cInducement Plan\u201d). The equity award was approved by the Compensation Committee of the Company\u2019s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee\u2019s acceptance of employment with Terns. The Company granted options to purchase 9,000 shares of Terns common stock … Continue reading \"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-02T21:10:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)","datePublished":"2025-01-02T21:10:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/"},"wordCount":275,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/","name":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=","datePublished":"2025-01-02T21:10:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNTg5OCM2Njc2OTA5IzIyMDQxNjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/terns-pharmaceuticals-reports-inducement-grant-to-new-employee-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=797565"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/797565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=797565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=797565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=797565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}